New method for monitoring lung cancer after surgery
Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer
This study is testing a new way to monitor lung cancer after surgery using blood tests to see if it helps patients stay cancer-free longer compared to standard methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06930807 on ClinicalTrials.gov |
What this trial studies
This study aims to develop innovative techniques for monitoring minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer after surgery. It will evaluate the effectiveness of adaptive treatment guided by ctDNA-MRD compared to traditional management methods. The research will also explore how different patient characteristics affect the outcomes of MRD-guided strategies. By utilizing liquid biopsy technology, the study seeks to enhance the sensitivity of detecting postoperative recurrence and improve patient survival rates.
Who should consider this trial
Good fit: Ideal candidates include adults with stage IA-IIIA non-small cell lung cancer who are planning to undergo curative surgery or neoadjuvant therapy.
Not a fit: Patients with advanced stage IIIB-IV non-small cell lung cancer or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective monitoring and treatment strategies for lung cancer patients, potentially improving survival rates.
How similar studies have performed: Other studies have shown promise in using liquid biopsy techniques for cancer monitoring, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy * Solid nodules \>1 cm or ground-glass nodules \>1.5 cm on imaging * No history of malignancies other than non-small cell lung cancer in the past 5 years * Specimens are well preserved and imaging documents are accessible. Exclusion Criteria: * Age\<18 years old * Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification) * Pathology results confirmed not to be non-small cell lung cancer * History of malignancies other than non-small cell lung cancer in the past 5 years
Where this trial is running
Beijing, Beijing Municipality
- Peking University People's Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Yintao Li, MD — Shandong Cancer Hospital and Institute
- Study coordinator: Kezhong Chen, MD
- Email: mdkzchen@163.com
- Phone: +86-010-88325983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.